2010 Guidelines Case Study #1 Mrs. DT 2010 Guidelines.
Using genetic markers in clinical practice David Thomas Advisor: Merck Clinical trial: Gilead and Merck.
Boceprevir Combined with Peginterferon alfa-2b/Ribavirin for Treatment-Naïve Patients with HCV Genotype 1 SPRINT-2 Final Results Mark S. Sulkowski, Fred.
HIV and Aging: a Time for a New Paradigm Amy C. Justice, MD, MSCE, PhD Professor, Yale University Section Chief, General Internal Medicine VA Connecticut.
1 This activity has been supported by an independent medical education grant from Bristol Myers Squibb. 2013 IC-HEP Educational supporters include Bristol.
Hepatitis web study Hepatitis web study Sofosbuvir + (Ledipasvir or GS-9669) +/- Ribavirin in GT-1 ELECTRON Trial (Arms 12-17 & 22) Phase 2 Treatment Naïve.
Practitioner’s Edge is a registered service mark of Integrity Continuing Education, Inc. © 2014 Integrity Continuing Education, Inc. Sponsored by Integrity.
CER Institute - Clinical Research
Highlights from CROI 18th Conference on Retroviruses and Opportunistic Infections Boston, MA February 28 to March 3, 2011 Iván Meléndez-Rivera, MD Assistant.
CONFIDENTIAL Investor Call December 9, 2010 Claire L. Kruger, Ph.D., Chief Executive Officer Robert A. Lodder, Ph.D., President.
N ORTHWEST AIDS E DUCATION AND T RAINING C ENTER New IDSA/AASLD Guidelines for Hepatitis C John Scott, MD, MSc Associate Professor, UW SoM Asst Director,
48-week results of once-daily maraviroc (MVC) 150 mg in combination with ritonavir-boosted atazanavir (ATV/r) compared to emtricitabine/tenofovir (FTC/TDF)